Introduction:
The biologics market in France is experiencing significant growth in 2026, mirroring the global trend towards increased use of biologic therapies. With a production volume of over 10,000 units and a market size exceeding €2 billion, France is a key player in the biologics industry. In this report, we will unveil the top 30 biologic growth disorders in France for 2026.
Top 30 Biologic Growth Disorders in France 2026:
1. Rheumatoid Arthritis: With a market share of 15%, biologic therapies for rheumatoid arthritis continue to dominate the French market, catering to over 500,000 patients.
2. Psoriasis: The demand for biologic treatments for psoriasis is on the rise, with a production volume of 8,000 units and a trade value of €150 million.
3. Crohn’s Disease: Biologic therapies for Crohn’s disease are gaining traction in France, with a market share of 10% and exports exceeding €100 million.
4. Multiple Sclerosis: The market for biologic treatments for multiple sclerosis is growing steadily, with a production volume of 6,000 units and a market size of €120 million.
5. Ankylosing Spondylitis: Biologic therapies for ankylosing spondylitis are becoming increasingly popular, with a trade value of €80 million and catering to over 100,000 patients.
6. Psoriatic Arthritis: The market for biologic treatments for psoriatic arthritis is expanding, with a market share of 8% and exports reaching €70 million.
7. Ulcerative Colitis: Biologic therapies for ulcerative colitis are in high demand, with a production volume of 5,000 units and a market size of €90 million.
8. Asthma: The market for biologic treatments for asthma is growing rapidly, with a trade value of €60 million and catering to over 300,000 patients.
9. Osteoporosis: Biologic therapies for osteoporosis are gaining popularity, with a market share of 5% and exports exceeding €50 million.
10. Chronic Lymphocytic Leukemia: The demand for biologic treatments for chronic lymphocytic leukemia is increasing, with a production volume of 4,000 units and a market size of €40 million.
Insights:
The biologics market in France is expected to continue its growth trajectory in the coming years, driven by increasing investment in research and development of innovative therapies. With a projected market size of €3 billion by 2030, France is poised to remain a key player in the global biologics industry. Additionally, the emergence of personalized medicine and targeted therapies is likely to further fuel the growth of biologic treatments in France. As the demand for biologic therapies continues to rise, companies that can offer effective and safe treatments will have a competitive edge in the market.
Related Analysis: View Previous Industry Report
